---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-052291"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2021-10-12T23:59:59+00:00"
generated_at: "2026-06-28T21:39:49.918761+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences licenses IRAK4 inhibitor KM10544 from Kainos for cancer treatment

## Summary
- Exclusive license for U.S., U.K., EU to Kainos' IRAK4 inhibitor KM10544 for cancers including leukemia, lymphoma, solid tumors.
- Six-figure upfront cash payment; mid-eight-figure milestones; single-digit royalty on net sales; similar sublicensing fee.
- Emmaus plans in-vivo studies, IND-enabling studies, and seeks Orphan Drug Designation.
- Agreement expands existing R&D collaboration between Emmaus and Kainos.

## SEC filing metadata
- accession: 0001213900-21-052291
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2021-10-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/0001213900-21-052291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/ea148129-8k_emmanus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-052291
- JSON: https://secwatch.observer/filing/0001213900-21-052291.json
- Plain text: https://secwatch.observer/filing/0001213900-21-052291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.